Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:5329098
Structure:
Synonyms:
"insolution™ vegf receptor 2 kinase inhibitor iii"
(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-o
(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one
194413-58-6
204005-46-9
2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-
2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)-
2H-Indol-2-one, 3-[(3,5-dimethyl-2-pyrrolyl)methylene]-
3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone
3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole
3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one
3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one
3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one
3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
C116890
D05819
EU-0101110
H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-
HSCI1_000303
InSolution™ VEGF Receptor 2 Kinase Inhibitor III
Lopac0_001110
LS-193151
LS-83886
MLS001074896
MLS001332519
MLS001332520
NCGC00094381-01
NCGC00094381-02
NCGC00094381-03
nchembio778-comp2
NSC-696819
NSC696819
S8442_SIGMA
Semaxanib
Semaxanib (USAN/INN)
Semaxanib [INN]
Semaxinib
Semaxnib
Semoxind
SMR000568416
SU 5416
SU-5416
SU5416
TSU-16
VEGF Receptor 2 Kinase Inhibitor III

Target

show target details
Uniprot ID:Q9Y354_HUMAN
Synonyms:
Matrix metalloproteinase 9
EC-Numbers:3.4.24.35
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

12657164
Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.. Samuel E DePrimo; Lily M Wong; Deepak B Khatry; Susan L Nicholas; William C Manning; Beverly D Smolich; Anne-Marie O'Farrell; Julie M Cherrington (2003) BMC cancer display abstract
BACKGROUND: Microarray-based gene expression profiling is a powerful approach for the identification of molecular biomarkers of disease, particularly in human cancers. Utility of this approach to measure responses to therapy is less well established, in part due to challenges in obtaining serial biopsies. Identification of suitable surrogate tissues will help minimize limitations imposed by those challenges. This study describes an approach used to identify gene expression changes that might serve as surrogate biomarkers of drug activity. METHODS: Expression profiling using microarrays was applied to peripheral blood mononuclear cell (PBMC) samples obtained from patients with advanced colorectal cancer participating in a Phase III clinical trial. The PBMC samples were harvested pre-treatment and at the end of the first 6-week cycle from patients receiving standard of care chemotherapy or standard of care plus SU5416, a vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor. Results from matched pairs of PBMC samples from 23 patients were queried for expression changes that consistently correlated with SU5416 administration. RESULTS: Thirteen transcripts met this selection criterion; six were further tested by quantitative RT-PCR analysis of 62 additional samples from this trial and a second SU5416 Phase III trial of similar design. This method confirmed four of these transcripts (CD24, lactoferrin, lipocalin 2, and MMP-9) as potential biomarkers of drug treatment. Discriminant analysis showed that expression profiles of these 4 transcripts could be used to classify patients by treatment arm in a predictive fashion. CONCLUSIONS: These results establish a foundation for the further exploration of peripheral blood cells as a surrogate system for biomarker analyses in clinical oncology studies.